Your browser doesn't support javascript.
loading
Immune checkpoint therapy-current perspectives and future directions.
Sharma, Padmanee; Goswami, Sangeeta; Raychaudhuri, Deblina; Siddiqui, Bilal A; Singh, Pratishtha; Nagarajan, Ashwat; Liu, Jielin; Subudhi, Sumit K; Poon, Candice; Gant, Kristal L; Herbrich, Shelley M; Anandhan, Swetha; Islam, Shajedul; Amit, Moran; Anandappa, Gayathri; Allison, James P.
Affiliation
  • Sharma P; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX
  • Goswami S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Raychaudhuri D; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Siddiqui BA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Singh P; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nagarajan A; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu J; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Subudhi SK; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Poon C; Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gant KL; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Herbrich SM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anandhan S; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; MD Anderson UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Islam S; Department of Head & Neck Surgery Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Amit M; Department of Head & Neck Surgery Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Anandappa G; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allison JP; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; James P. Allison Institute, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cell ; 186(8): 1652-1669, 2023 04 13.
Article in En | MEDLINE | ID: mdl-37059068
ABSTRACT
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer patients and conferred durable clinical benefits, including cure in a subset of patients. Varying response rates across tumor types and the need for predictive biomarkers to optimize patient selection to maximize efficacy and minimize toxicities prompted efforts to unravel immune and non-immune factors regulating the responses to ICT. This review highlights the biology of anti-tumor immunity underlying response and resistance to ICT, discusses efforts to address the current challenges with ICT, and outlines strategies to guide the development of subsequent clinical trials and combinatorial efforts with ICT.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cell Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunotherapy / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Cell Year: 2023 Document type: Article